Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess Authors: Yiheng Li, Jing Zhu, Qian Guo, Jiaman Liao, Lixia Li, Jing Hu, Xiaoliang Zhang, Eshetie Birru, Rajeev Singh, Rajeev Singh Published: 2026 ABSTRACT IntroductionAntihistamines like azelastine and levocabastine are key in treating allergies, including allergic rhinitis, conjunctivitis, and urticaria. This study analyzed adverse drug reactions linked to these drugs using data from the WHO VigiAccess database, comparing their adverse drug reaction profiles to help physicians choose lower-risk options for personalized treatment.MethodsA retrospective descriptive analysis was used, with data from WHO-VigiAccess on azelastine and levocabastine. Included were global patient demographics (age, gender, location) and details on illness systems/symptoms from direct and annual adverse drug reaction reports. Adverse drug reaction percentages for each drug were calculated for comparison.ResultsOver the study period, 11,592 adverse events related to both drugs were reported. Both had high rates of General disorders and administration site conditions. Azelastine showed more Nervous system disorders. Levocabastine had higher rates of endocrine disorders, injury/poisoning/procedural complications, and Nervous system disorders. The top five adverse events were: General disorders (4463, 36.7%), Nervous system (3475, 28.6%), Gastrointestinal (1558, 12.8%), Respiratory (1515, 12.5%), and Injury/poisoning (871, 7.2%). For SOC-reported ADRs, > 10% incidence occurred in 2 azelastine cases and 4 levocabastine cases.ConclusionClinicians should note antihistamine ADRs. This study identifies common and specific reactions reported to the WHO, aiming to guide safer, more judicious use of these drugs. Introduction Allergic rhinitis (ARs) is a prevalent chronic inflammatory condition with a global prevalence of up to 40%, exhibiting a rising trend in recent years, making it a significant global public health issue [1–3]. It usually manifests as runny nose, nasal congestion, sneezing, itchy nose, itchy eyes, and itchy throat, and so on [3]. Clinically, nasal mucosal congestion, increased secretion of nasal contents, as well as pale edema of the turbinates, can be observed [4]. This condition significantly impacts the patient’s quality of life and physical and mental health [5]. ARs episodes usually exhibit a seasonal or intermittent pattern and are highly prevalent in seasons when allergens (e.g., pollen, willow, dust mites, molds, and so on) increase. During pathogenesis, allergens entering the nasal cavity stimulate the nasal mucosa, penetrating the epithelial barrier, which are then taken up and processed by antigen-presenting cells [5]. This leads to the differentiation of naïve T cells into Th2 helper T cells capable of releasing cytokines (e.g., IL-4, IL-5). This results in the generation of B cells with allergen-specific IgE that bind to high-affinity IgE receptors on mast cells, Langerhans cells, monocytes, and basophils. Upon subsequent encounters with the allergen, the associated antigenic determinant cluster (i.e., a 7–8 amino acid peptide) is recognized by the IgE molecule in the region of the specific IgE antigen-binding site (which binds to mast cells and basophils), resulting in mast cell activation and release of biologically active mediators, such as histamine, leukotrienes, and platelet-activating factor. Binding of these mediators to receptors on blood vessels, mucus-secreting glands, and sensory nerves induces physiologic responses associated with ARs symptoms [6–9] (Fig 1). Effective treatment strategies encompass the use of mast cell stabilizers, antihistamines, glucocorticoids (GCS), leukotriene receptor antagonists, and nasal decongestants [10,11]. The combination therapy most frequently employed, involving nasal GCS administration and antihistamines, is currently regarded as the most effective treatment option [12]. Pathogenesis of allergic rhinitis. Allergens penetrating the nasal epithelial barrier are taken up by antigen-presenting cells, which promote the differentiation of naive T cells into Th2 cells. Th2-derived cytokines drive allergen-specific IgE production by B cells. IgE binds to high-affinity receptors on mast cells and basophils. Upon allergen re-exposure, IgE cross-linking triggers mast cell degranulation and the release of mediators such as histamine, leukotrienes, and platelet-activating factor, which act on blood vessels, mucus glands, and sensory nerves to produce AR symptoms. Histamine exerts a significant role in the pathogenesis of AR. In the early allergic immune response, elevated mast cell activity leads to the release of histamine, that binds to H1 receptors on nasal mucosal epithelial cells, mediating increases in vascular permeability and a lowering of the epithelial barrier, bronchial smooth muscle contraction, and the recruitment of inflammatory factors [12,13]. Antihistamines such as azelastine and levocabastine are capable of inhibiting histamine-mediated allergic reactions through competitive binding to the H1 receptor with histamine, thus achieving therapeutic effects [14]. Azelastine, a phthalazinone derivative, is a second‑generation antihistamine and a selective H1‑receptor antagonist. It exhibits unique pharmacological properties by inhibiting the synthesis and/or expression of various chemical mediators of allergic reactions [15], such as leukotrienes, kallikreins, cytokines, chemokines, and superoxide radicals [16,17]. Levocabastine is also a second‑generation antihistamine and a selective, long‑acting H1‑receptor antagonist administered via the nasal and ocular routes. In controlled trials, levocabastine has been shown to be both efficacious and well‑tolerated in the treatment of AR and allergic conjunctivitis [18,19]. Clinically utilized antihistamine nasal sprays have undergone numerous animal and clinical trials leading to their clinical use. While offering therapeutic benefits, side effects are inevitable. Clinical evidence indicates that first-generation antihistamines cross the blood-brain barrier and have sedative and drying effects on patients. Second-generation antihistamines generally exhibit better tolerability and have reduced sedative and drying effects. Intranasal antihistamines may result in hyperemia and desiccation of the nasal mucosa, with epistaxis and, in some cases, headache. Other drugs for ARs, such as leukotriene modulators (e.g., montelukast), have been linked to anxiety, depression, and nightmares in some patients. Cortisol drugs also commonly induce adverse effects such as nosebleeds, and in a few patients, nasal ulcers and septal ulcers [20]. While all marketed drugs are subject to rigorous clinical trials and long-term adjustments, the sample size in such experiments is inherently limited, and it cannot fully anticipate all the symptoms that may occur when the drug is used in various types of patients, nor predict interactions with other medications in patients with multiple comorbidities [21]. Thus, more study is warranted on drug safety evaluation based on big, real-world sample data. This study identified two antihistamine nasal sprays approved by the U.S. Food and Drug Administration (FDA) for the treatment of AR, including azelastine and levocabastine. A descriptive analysis of spontaneously reported adverse drug reactions (ADRs) in VigiAccess was carried out, and the reporting rates of adverse responses between the two pharmaceuticals were compared, in an effort to clarify the parallels and differences in adverse reactions between these two medications. In this study, we used disproportionate analyses ADR signals included in the Vigiaccess database.The study aimed to detect new and unexpected ADRs not described in the drug label. Given the paucity of research on the comparison of adverse reactions between these two drugs, this study aims to offer a theoretical basis for clinicians when selecting drugs to treat patients with different ARs. Materials and methods Drug sample Table 1 presents the drug structures, main indications, and targets of action of the two drugs primarily studied in this article. Both azelastine and levocabastine are H1-receptor antagonists, effective in the treatment of ARs and allergic conjunctivitis. Azelastine has been in clinical use since 1986, predating the commercialization of levocabastine. Azelastine is primarily administered as a nasal spray for the treatment of seasonal and perennial ARs and has demonstrated efficacy in managing urticaria. Levocabastine, available in the form of nasal sprays and eye drops, is commonly employed for symptomatic relief of ARs and allergic conjunctivitis. These medications have been in clinical use for over two decades and are accessible in China. Other antihistamines, including loratadine, cetirizine, and olopatadine, are instrumental in the management of ARs. 10.1371/journal.pone.0355852.t001Table 1General information on two antihistamine agents.Drug name and brand nameMain conditionsDrug targetFirst marketing timeAzelastineallergic rhinitis, allergic conjunctivitis, urticariaH1-R1986Levocabastineallergic rhinitis, allergic conjunctivitisH1-R1993 General information on two antihistamine agents. Date sources All data used in the article was obtained from the WHO-VigiAccess website (https://www.vigiaccess.org). We obtained all adverse events (AEs) that occurred after using each medication as of August 31, 2024, using the brand and generic names of the medication. The WHO information system gathers information on age group, sex, reporting year, and the world’s major continents. Excel 2016 was used to examine descriptive data. The PIDM database is accessible through the free site WHO-VigiAccess. Users can access drug safety reports that the UMC has received. The definitions are based on the Medical Dictionary of Regulatory Activities (MedDRA) system organ categories (SOCs) and preferred terms (PTs). Therefore, a search was conducted of the records for each antihistamine, and individual AEs were identified employing the MedDRA SOC and PT criteria to examine the range of toxicities. A number of dictionaries, including the World Health Organization Adverse Reaction Terminology (WHO-ART), are the source of words used in MedDRA. According to MedDRA, there are 20 SOCs, and a thorough analysis was conducted of those directly related to disease symptoms. This study concentrated on PTs, which were aggregated data publicly available from the VigiBase database through WHO-VigiAccess. The spontaneous reporting system, introduced in the 1960s, remains the backbone of pharmacovigilance [22]. The primary goal of spontaneous reporting is the early identification of AEs that were previously undetected. Furthermore, spontaneous reporting facilitates the acquisition of new insights into known drug-adverse reaction associations. Global safety data is compiled by the Uppsala Monitoring Centre (UMC) on behalf of the WHO’s International Drug Monitoring (PIDM). Through VigiBase, the global voluntary reporting program, UMC has gathered and preserved over 20 million ADR reports from over 170 countries by December 2018 [23]. Since 2015, public access to the data stored in VigiBase has been provided through VigiAccess. VigiAccess databases support searches by the trade name of a drug product, which then identifies the active ingredient(s) contained and displays the ADR report results based on these active ingredient(s). Statistical analysis This study utilized a retrospective quantitative research design. Descriptive analysis using Excel was conducted to analyze the characteristics of ADR profiles for two drugs. The number of ADR symptoms divided by the total number of ADR complaints was used to get the ADR reporting rate for each medication. Based on the top 20 symptoms with the greatest rates of ADR reporting, common ADRs for each medicine were determined. For the purpose of a descriptive comparison, the incidence of ADR symptoms recorded for each drug was computed and examined. Descriptive variables were organized using frequencies and percentages. Adverse event data were retrieved from the WHO-VigiAccess database. Using Python 3.10 with the requests library, the BASENAMEs of all drugs in the WHODRUG dictionary were queried, and the JSON data returned from the front-end pages were collected. The data were then structured and visualized using the Pandas library and exported to Excel spreadsheets. All subsequent disproportionality analyses, including the calculation of ROR, PRR, and their 95% confidence intervals, were performed using SAS 9.4 software. The individual case safety reports (ICSRs) retrieved from VigiAccess were further screened according to the following criteria. Only ICSRs in which azelastine or levocabastine was recorded as a “suspected” drug were included in the analysis. Reports where these antihistamines were coded exclusively as “concomitant” medications were excluded. To ensure data quality, duplicate reports, identified by matching report identifiers, and reports with missing or incomplete adverse event information were excluded. After applying these criteria, all eligible ICSRs were retained for disproportionality analysis. Disproportionality analysis We used the Reporting Odds Ratio (ROR) and the Proportional Reporting Ratio (PRR) as two disproportionality reporting methodologies based on the disproportionality analysis. A common technique in pharmacovigilance, the measure of odds imbalance serves as the foundation for the computation of ROR and PRR. ROR quantifies the odds imbalance of reporting AEs for a specific drug relative to other drugs and is defined by the following equation: where (a) is the number of reports of a specific drug and a specific AE, (b) is the number of reports of the same drug with other AEs, (c) is the number of reports of other drugs with the same AE, and (d)is the number of reports of other drugs with other AEs. The statistical robustness of the ROR calculation is dependent upon the presence of at least 5 cases (a ≥ 5) of a particular drug and adverse event combination. PRR is an additional metric used to quantify the disproportionality of AE reports and is calculated using the following formula: and like ROR, requires at least 5 cases (a ≥ 5) of a specific drug and AE combination to be considered valid. The signal is deemed disproportionate and may raise safety concerns if the ROR value is more than two (ROR > 2) and the lower limit of the 95% confidence interval (CI) for the ROR is greater than one (lower limit of the 95% CI for ROR > 1). By using these criteria, it is ensured that random variation cannot be the cause of the observed disproportionality. The calculation formulas, standard errors, 95% confidence intervals, and signal detection criteria are summarized in Table 2. 10.1371/journal.pone.0355852.t002Table 2The principles of disproportionate measurement and the criteria for signal detection.MethodCalculation formulaCriteriaROR ROR=a / cb / d a ≥ 395%CI (lower limit) > 1 SE(lnROR)=1a+1b+1c+1d 95%CI= eln(ROR)±1.96se PRR PRR=a / (a+b)c / (c+d) a ≥ 395%CI (lower limit) > 1 SE(lnPRR)=1a−1a+b+1c−1c+d 95%CI= eln(PRR)±1.96se χ2 = (ad−bc)2(a+b+c+d)( a+b)(a+c)(c+d)(b+d) a ≥ 3PRR ≥ 2χ2≥4 The principles of disproportionate measurement and the criteria for signal detection. In our analysis, the application of ROR and PRR permitted a systematic assessment of the disproportionality of adverse reactions reported with antihistamines. The analysis’s findings support efforts in pharmacovigilance that try to improve drug safety. For the targeted analysis of neurological disorders, all AEs coded to PTs belonging to the MedDRA SOC “Nervous system disorders” were included. The specific PTs identified for azelastine and levocabastine in this SOC comprised: burning sensation, hypoaesthesia, ageusia, migraine, paraesthesia, balance disorder, headache, parosmia, tremor, sedation, dysgeusia, dizziness, anosmia, and somnolence. No further restriction at the High-Level Term (HLT) or High-Level Group Term (HLGT) level was applied. In all disproportionality analyses, the reference group for each drug–ADR pair consisted of all other drug–ADR combinations in the WHO-VigiAccess database. Specifically, the 2 × 2 contingency table was constructed with the study drug and target ADR as the index pair (cells *a* and *b*), while all other drugs and all other ADRs in the database served as the background comparator (cells *c* and *d*), as defined in the formulas above. Ethics statement Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and the institutional requirements. Results General characteristics of the cases studied Adverse reaction reports for the drugs azelastine and levocabastine were first received in the WHO-VigiAccess database in 1988 and 1992, respectively. As of 2024, the WHO database contained 10, 793 and 799 ADR reports for these two drugs, totaling 11, 592. The numbers of AEs covered in these ADR reports were 15,330 for azelastine and 1,292 for levocabastine. Table 3 displays, among the 11, 592 reports of these two antihistamines, excluding 972 cases of unknown gender, the number of ADRs reported in females (7, 262, 62.65%) was higher than that of males (3, 376, 29.12%), with a male-to-female ratio of 2.15:1 and a gender difference. After exclusion of reports without age information, the most frequently reported age group for AEs was 45–65 years for azelastine, compared to 18–44 years for levocabastine. Over half of the reported cases of azelastine occurred in the Americas, and close to 90% of the cases of levocabastine occurred in Europe. Table 3 also lists the year of reporting for each study drug. Both drugs were documented through 2010. Over the past decade, azelastine exhibited the highest ADR incidence in 2020 and was also higher in 2016 and 2023 than in other years; levocabastine exhibited a higher ADR incidence in 2022 than in other years. ADR incidence rates for both drugs have shown an increasing trend over the past decade, excluding years with significant increases. 10.1371/journal.pone.0355852.t003Table 3Characteristics of ADR reports of two antihistamines.AzelastineLevocabastine Number of ADR reports 10793799 Female 6820 (63.2%)442 (55.3%) Male 3160 (29.3%)216 (27.0%) Unknown 813 (7.5%)141 (17.6%) 0 - 27 days 15 (0.1%)1 (0.1%) 28 days to 23 months 5 (0.1%)3 (0.4%) 2 - 11 years 131 (1.2%)55 (6.9%) 12 - 17 years 134 (1.2%)28 (3.5%) 18 - 44 years 1736 (16.1%)199 (24.9%) 45 - 64 years 2383 (22.1%)140 (17.5%) 65 - 74 years 1147 (10.6%)47 (5.9%) ≥ 75 years 785 (7.3%)38 (4.8%) Unknown 4457 (41.3%)288 (36.0%) Africa 4 (0.0%)6 (0.8%) Americas 5606 (51.9%)26 (3.3%) Asia 3665 (34.0%)34 (4.3%) Europe 1484 (13.7%)704 (88.1%) Oceania 34 (0.3%)29 (3.6%) 2024 883 (8.2%)31 (3.9%) 2023 1239 (11.5%)59 (7.4%) 2022 371 (3.4%)149 (18.6%) 2021 503 (4.7%)40 (5.0%) 2020 2385 (22.1%)50 (6.3%) 2019 744 (6.9%)40 (5.0%) 2018 663 (6.1%)47 (5.9%) 2017 537 (5.0%)17 (2.1%) 2016 1188 (11.0%)38 (4.8%) 2015 449 (4.2%)26 (3.3%) Before 2014 1831 (17.0%)302 (37.8%) Characteristics of ADR reports of two antihistamines. Distribution of 27 SOCs for 2 antihistamines Table 4 displays the rate of 27 SOC reports for the 2 antihistamines. The highest rates of adverse reactions observed in both azelastine and levocabastine were General disorders and administration site conditions. Furthermore, azelastine treatment exhibited a higher incidence of adverse reactions for Nervous system disorders. Levocabastine treatment also exhibited higher rates of endocrine disorders, AEs related to injury, poisoning, and procedural complications, and Nervous system disorders were also higher than in other groups. 10.1371/journal.pone.0355852.t004Table 4ADR number and report rate of 27 SOCs of two antihistamines.Azelastine(N = 15330)Levocabastine(N = 1292) Blood and lymphatic system disorders 17 (0.11%)2 (0.15%) Cardiac disorders 180 (1.17%)24 (1.86%) Congenital familial and genetic disorders 7 (0.05%)1 (0.08%) Ear and labyrinth disorders 85 (0.55%)7 (0.54%) Endocrine disorders 4 (0.03%)261 (20.20%) Eye disorders 801 (5.23%)– Gastrointestinal disorders 1506 (9.82%)52 (4.02%) General disorders and administration site conditions 4183 (27.29%)280 (21.67%) Hepatobiliary disorders 16 (0.10%)1 (0.08%) Immune system disorders 219 (1.43%)30 (2.32%) Infections and infestations 268 (1.75%)56 (4.33%) Injury poisoning and procedural complications 739 (4.82%)132 (10.22%) Investigations 270 (1.76%)11 (0.85%) Metabolism and nutrition disorders 116 (0.76%)3 (0.23%) Musculoskeletal and connective tissue disorders 152 (0.99%)13 (1.01%) Neoplasms benign malignant and unspecified incl cysts and polyps 17 (0.11%)1 (0.08%) Nervous system disorders 3340 (21.79%)135 (10.45%) Pregnancy puerperium and perinatal conditions 9 (0.06%)3 (0.23%) Product issues 649 (4.23%)32 (2.48%) Psychiatric disorders 441 (2.88%)37 (2.86%) Renal and urinary disorders 108 (0.70%)4 (0.31%) Reproductive system and breast disorders 39 (0.25%)– Respiratory thoracic and mediastinal disorders 1399 (9.13%)116 (8.98%) Skin and subcutaneous tissue disorders 582 (3.80%)71 (5.50%) Social circumstances 27 (0.18%)3 (0.23%) Surgical and medical procedures 28 (0.18%)5 (0.39%) Vascular disorders 128 (0.83%)12 (0.93%) ADR number and report rate of 27 SOCs of two antihistamines. The five most common AEs included General disorders and administration site conditions (4463, 36.7%), Nervous system disorders (3475, 28.6%), Gastrointestinal disorders (1558, 12.8%), Respiratory, thoracic, and mediastinal disorders (1515, 12.5%), and Injury, poisoning, and procedural complications (871, 7.2%). Of the SOC-reported ADRs, the incidence of more than 10% occurred in 2 cases of azelastine and 4 cases of levocabastine. Disproportionation analysis based on neurological disorders By observing and comparing the SOC distribution of the two antihistamines, our analysis revealed that neurological disorders were the most frequently reported AEs. To further compare the two drugs, we conducted a signal disambiguation analysis focusing on neurological disorders. We employed the ROR and PRR methods. Table 5 presents the results of the signal disambiguation analysis, revealing the following ROR values for the two drugs: azelastine: 2.48 (2.10–2.92); levocabastine: 0.40 (0.34–0.48). The results suggest that azelastine is associated with a higher likelihood of neurologic disorders compared to levocabastine. 10.1371/journal.pone.0355852.t005Table 5Disproportionation analysis based on neurological disorders.ROR (95%CI)PRR (95%CI) Azelastine 2.48 (2.10-2.92)2.16 (2.10-2.93) Levocabastine 0.40 (0.34-0.48)0.46 (0.34-0.48) Disproportionation analysis based on neurological disorders. The most common adverse effects of the two antihistamines Table 6 lists the 10 most frequently reported ADRs for the two medications, expressed as preferred terminology from the SOC. Common adverse reactions for both antihistamines included drowsiness, drug inefficacy, dizziness, eye irritation, headache, nausea, epistaxis, fatigue, dyspnea, and pruritus. Adverse reactions such as treatment failure, taste reversal, and dry mouth were particularly associated with azelastine, whereas adverse reactions such as unexpected treatment response, eye pain, and ocular congestion were particularly associated with levocabastine. 10.1371/journal.pone.0355852.t006Table 6Top 10 ADRs of antihistamines.AzelastineLevocabastineADRReport rateADRReport rate Treatment failure 9.81%Therapeutic response unexpected4.91% Somnolence 7.37%Off label use4.35% Dysgeusia 5.05%Eye irritation4.29% Drug ineffective 4.69%Headache3.48% Dizziness 2.62%Fatigue3.42% Eye irritation 1.99%Eye pain3.04% Dry mouth 1.91%Epistaxis2.80% Headache 1.83%Ocular hyperaemia2.11% Nausea 1.40%Vision blurred2.05% Nasal discomfort 1.28%Drug ineffective1.80% Top 10 ADRs of antihistamines. Serious adverse reactions to two antihistamines The WHO-VigiAccess allowed us to identify the major AEs, including life-threatening events, disability, and congenital malformations, for the two main antihistamines studied in this paper. The incidence of serious AEs was 0.07% for azelastine and 0.08% for levocabastine. Although most of the adverse effects are mild and related to the individual patient’s constitution, there are some serious adverse effects such as hypertensive crisis and congenital malformations that require hospitalization or may even lead to patient death. No serious adverse reactions involving disability or congenital malformations have been identified with levocabastine. Similarities and differences in common adverse effects of these two antihistamines By comparing the top 10 ADRs reported in the SOC for both antihistamines, a total of 130 identical signals were found in the PTs. All common signals were categorized and presented in S1 Table. The SOC with the highest number of ADR signals was Respiratory, thoracic, and mediastinal disorders. The top five identical ADR signals were respiratory, thoracic, and mediastinal disorders, eye disorders, general disorders and administration site conditions, nervous system disorders, and gastrointestinal disorders. The two drugs also each had different adverse reactions (see S2 Table), which are shown in the charts and are not described here. As can be seen from the figure, azelastine has unique adverse effects in gastrointestinal disorders, general disorders and administration site conditions, injury, poisoning, and procedural complications, and product issues, while levocabastine has unique adverse effects in immune system disorders, infections and infestations, injury, poisoning, and procedural complications, psychiatric disorders, skin and subcutaneous tissue disorders, and other unique adverse reactions. Discussion This study, based on the WHO-VigiAccess database, analyzed the post-marketing adverse event reporting characteristics of azelastine and levocabastine. By 2024, a total of 11,592 reports had been included (10,793 for azelastine and 799 for levocabastine), involving 15,330 and 1,292 AEs, respectively. The proportion of female reports was significantly higher than that of male reports (62.65% vs. 29.12%). The peak age group was 45–65 years for azelastine and 18–44 years for levocabastine. Geographically, reports for azelastine mainly originated from the Americas, whereas nearly 90% of reports for levocabastine came from Europe. The most common adverse reactions overall were general disorders and administration site conditions, followed by nervous system disorders. Frequently reported adverse reactions shared by both drugs included somnolence, dizziness, headache, nausea, fatigue, dyspnoea, and epistaxis. The incidence of serious adverse reactions was less than 0.1% for both drugs, and no reports of disability or congenital malformation were identified for levocabastine. Signal comparison identified 130 shared preferred term (PT) signals, which predominantly involved the respiratory, nervous system, and general disorders system organ classes. Meanwhile, the two drugs exhibited unique adverse reaction profiles in areas such as endocrine disorders and eye disorders. According to the data analysis, the incidence of adverse reactions in both azelastine and levocabastine was significantly higher in females than in males, with a significant gender difference. Studies have confirmed that allergic responses vary significantly throughout a woman’s reproductive life [24,25]. and that female sex hormones such as estrogen and progesterone enhance immune function, whereas male sex hormones such as testosterone suppress immune function, leading to a higher lifetime incidence of allergic disease in women than in men [26]. In addition, data analysis from Denmark has shown that the rate of ARs sensitization in women is increasing yearly in recent years, which may be one of the reasons for the high incidence of adverse reactions in women [27]. Azelastine and levocabastine have the highest concentration of adverse reactions in the age range of 18–64 years, likely because adults have a well-developed and fully functioning immune system and are more susceptible to ARs due to their stronger immune function compared to minors and the elderly [28]. This suggests that the exact correlation needs to be further investigated. Geographically, differences in the incidence of adverse reactions between the two drugs were observed; for azelastine, half of the adverse reaction instances originated in the Americas, whereas nearly 90% of the adverse reaction instances for levocabastine originated in Europe. This may be closely related to the prescribing habits of physicians in different countries. At the same time, we cannot rule out the regional influence caused by differences in population size across continents and variations in awareness of spontaneous adverse event reporting among healthcare institutions. For example, the low adverse reaction reporting rates in Africa and Oceania are associated with low drug utilization and differences in healthcare professionals’ knowledge of the drugs, a situation further exacerbated by the high cost of many drugs and complex procurement procedures [29]. No geographical studies on ARs are available now. Apart from years with notably higher data, both azelastine and levocabastine showed a yearly increase in the incidence of adverse reactions, which, in addition to the yearly increase in sensitization rates among adults, may be related to the new coronavirus in late 2019. Studies have shown that the likelihood of developing anaphylaxis after COVID-19 infection is greatly increased [30,31]. The elevated incidence of allergic disease has led to increased utilization of both drugs, which may be one reason for the continued increase in reported instances of adverse reactions. Comparison of the adverse reaction signals for the two drugs revealed that both azelastine and levocabastine exhibited the characteristic side effects of antihistamines, namely sedation and drying effects, and the sedative effect of azelastine is more pronounced when taken with alcohol [32]. Respiratory symptoms were particularly prominent; nasal discomfort, sore throat, wheezing, nasal dryness, and dyspnea were common adverse reactions shared by both drugs. In addition, we observed that the incidence of nervous system adverse reactions exceeded 10% for both drugs, and nervous system adverse reactions accounted for the highest proportion among the adverse reaction reports for azelastine. Studies have shown that azelastine has a certain ability to cross the blood–brain barrier and, under specific experimental conditions, can induce cytotoxic effects and inhibit the proliferation of glioblastoma cell lines [33]. Furthermore, it was observed that the incidence of neurologic adverse reactions exceeded 10% for both drugs. Neurologic adverse reactions common to both drugs encompass loss of taste, loss of smell, balance disorders, headache, olfactory inversion, tremor, sedation, vertigo, and somnolence. Moreover, azelastine has been associated with adverse reactions such as seizures, loss of consciousness, and hypotonia [15,34]. Experimental evidence from canine studies has demonstrated that azelastine can induce constitutional generalized seizures, potentially elucidating the mechanism behind seizure-related adverse reactions [35]. Extensive research on azelastine indicates that it is commonly associated with sedative effects post-administration. Levocabastine is also linked to distinct neurologic adverse reactions, such as attention deficit, brain fog, mucous membrane burning sensation, dystonia, and facial palsy. Levocabastine functions as both an H1 receptor antagonist and an antagonist of the neurohypocretin NTS2 receptor [36]. Neurohypocretin is an endogenous neuropeptide that binds to the NTS2 receptor and promotes neuronal calcium inward flow, thereby participating in cellular signaling. In the central nervous system, levocabastine can act as an NTS2 receptor antagonist, thereby inhibiting NO synthase activity and regulating mitochondrial function [37]. The use of levocabastine also has an effect on Na-K-ATPase activity [38]. These processes play an important role in neural nociceptive signaling. It is plausible to infer that adverse effects such as headaches experienced by patients are associated with NTS2 signaling pathways. We also observed in the data that adverse reactions related to endocrine disorders accounted for the largest proportion of reports for levocabastine, exceeding 20% of the total AEs. This is closely linked to the role of the neuropeptide neurotensin (NT). A study on the effects of NT showed that levocabastine, acting as an NTSR agonist, exhibited a protective effect on pancreatic cells similar to that of NT and may participate in regulating certain endocrine pancreatic functions [39]. Although the present study focused on intranasal antihistamines, the AEs analyzed underscore the importance of limiting these drugs to their approved indications. Indiscriminate use of these agents in non-allergic conditions such as uncomplicated dry eye or viral conjunctivitis may expose patients to the neurological and respiratory adverse effects reported herein without clear therapeutic benefit. This principle of prudent prescribing applies not only to otorhinolaryngology but also to all other clinical settings where these two antihistamines may be used. We therefore hope that this paper may serve as a reference for clinicians in practicing prudent medication use. Utilizing spontaneous reporting system databases, such as VigiAccess, entails inherent limitations. The variability in the number of reports for each drug, coupled with differing geographical usage patterns and regional habits, can result in a regional skew in adverse reaction reports [40]. Consequently, patterns identified may not be generalizable across different regions. Furthermore, reporting is influenced by regional development levels, with less developed areas potentially lacking the infrastructure and awareness necessary for comprehensive reporting, leading to potential data omissions. In certain instances, the missing data precludes demographic attribution. Additionally, owing to its cumulative data structure, the VigiAccess database does not provide annual ADR breakdowns, leading to variations in the number of collected ADRs for drugs marketed at different times and complicating direct comparisons of signaling profiles. Thus, extensive data mining may not be feasible. To mitigate this, this study collected data on ADRs and PTs for both drugs up to August 31, 2024. The findings of this study were limited to the relative outcomes of the two antihistamines, azelastine and levocabastine. Conclusion Antihistamines play a crucial role in the treatment of ARs. Studies have shown that WHO-VigiAccess has reported no less than 10, 000 cases of adverse reactions to both azelastine and levocabastine treatments. These adverse reactions were characterized by respiratory dysfunction and neurological abnormalities, consistent with previous studies confirming symptoms such as respiratory burning sensation, mucosal dryness, sedation, and vertigo. In addition, levocabastine, which is also an NTS2 antagonist, was associated with more prominent adverse effects than azelastine in terms of neurologic dysfunction. Although serious AEs accounted for only a small proportion of reports for both drugs, this finding should not be overlooked. Conducting safety studies of pharmaceutical products, including cohort event monitoring, is essential for governments to determine the causal association between adverse responses and pharmaceuticals. These results might also be made publicly available through open access repositories to raise awareness of side effects connected to biotechnology-based medications. Supporting information Same ADRs between two antihistamines. (DOCX) Different ADRs between two antihistamines. (DOCX) 15 Apr 2026 Dear Dr. LI, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 30 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Eshetie Melese Birru, PhD Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 3. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement. 4. Thank you for stating the following financial disclosure: This research was partially funded by the National Natural Science Foundation of China (82071023), the Key Project of Medical Science and Technology of Henan Province (SBGJ202102160), and the Scientific Research Project of Colleges and Universities in Henan Province (21A320053). Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: I Don't Know Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: Ophthalmologists often come across allergic clinical entities such as vernal keratoconjunctivitis, atopic conjunctivitis and seasonal conjunctivitis; it becomes imperative to prescribe topical antihistamine eyedrops in such patients and the given article appropriately highlights the ADRs of these medications. It is to be emphasized that the use of these eyedrops be limited to the above-mentioned conditions. Keeping in line with the ADRs highlighted in the study, they should be avoided as a blanket therapy in uncomplicated cases of dry eye syndrome and viral conjunctivitis - two very commonly encountered conditions where antihistamines are often indiscriminately prescribed by clinicians. Reviewer #2: The manuscript provides a clear and concise overview of spontaneously reported AEs for 2 antihistamine drugs. Several comments and suggestions have been identified which should be considered by the authors. - The pathogenesis of AR is clearly described. To improve readability, consider to include a figure for the pathogenesis. - Lines 67-73: The information in this section is not consistent as both drugs are second generation antihistamines and are selective H1-antagonists. In the current version it is specifically stated that azelastine is a second generation antihistamine and levocabastine is a selective H1-receptor antagonist. As this applies to both antihistamines the authors are advised to amend the manuscript accordingly. - Lines 88-100: This information is better placed in the methods section of the manuscript. Please amend. - Lines 120-124: From the information in the methods section it can not be deduced when ICSRs are selected and excluded. Within spontaneous reports medicines can be either classified by the reporter as suspected or concomitant. Which reports are included in the current study? And are any exclusion criteria applied? - Line 128: anti-VEGF drug need to be replaced by antihistamine drugs. - Disproportionality analysis: Please add which statistical software was used to calculate the ROR and PRR. - Line 137: Shouldn’t 5 drugs be replaced by 2 drugs? - Lines 170-173: The authors are advised to include the number of Adverse Events in addition to the number of reports currently included. - Lines 175 and 176: Please remove the word significant from these sentences as no statistics are applied. - Table 2: Consider shortening this table by combining age groups and years of reporting. - Lines 202-210: MAJOR: The authors should specify which AEs were included in the analysis on neurological disorder and from the methods section and the results section it does not become clear which reference group is used for the analysis to calculate the ROR and PRR. Please specify. - Table 5: Consider to shorten this table by only presenting the 10 most frequently reported AEs. - Figure 1 does not add relevant information, consider to delete. - Table 6 & 7: These tables are quite extensive and have limited added value. Consider to move these tables to the supplementary information. - Discussion section: MAJOR: start with a summary of the main findings and discuss the findings in relation to previous studies in the following paragraphs. Please amend. In addition, the information in lines 259-278 is a repetition of the information already described in the introduction section. Please delete. - From the results section it is interesting to note the difference in AE reports between the two antihistamines. Consider to discuss this difference in the discussion section. - Lines 304-319: Please shorten this section and try to avoid repetition of the information already included in the results section. - Lines 364-365: Consider to replace this specific information to the results section. - Line 365: It is not clear why the term biologics is introduced as both drugs studied are not biologics. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Isha Chaturvedi Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 21 May 2026 Dear Editor and Reviewers: We sincerely thank you for your time, effort, and insightful feedback on our manuscript. The constructive comments provided have been invaluable in improving the clarity and overall quality of our work. In response, we have carefully revised the manuscript based on the reviewers' suggestions and have made every effort to minimize grammatical errors. To facilitate the review process, we are providing a clean version of the manuscript as well as a marked version with all track changes. Additionally, a detailed, point-by-point response to each comment has been included. We are deeply appreciative of the meticulous attention given to our manuscript and sincerely hope that the revised version now fulfills the criteria for publication. Reviewer #1: Ophthalmologists often come across allergic clinical entities such as vernal keratoconjunctivitis, atopic conjunctivitis and seasonal conjunctivitis; it becomes imperative to prescribe topical antihistamine eyedrops in such patients and the given article appropriately highlights the ADRs of these medications. It is to be emphasized that the use of these eyedrops be limited to the above-mentioned conditions. Keeping in line with the ADRs highlighted in the study, they should be avoided as a blanket therapy in uncomplicated cases of dry eye syndrome and viral conjunctivitis - two very commonly encountered conditions where antihistamines are often indiscriminately prescribed by clinicians. Response: We are very grateful for the reviewer’s positive evaluation of our manuscript, and we are truly honored by your recognition. We also sincerely thank the reviewer for the insightful clinical perspectives shared from the viewpoint of ophthalmic indications. Although this paper primarily focuses on the use of antihistamines in allergic rhinitis, the reviewer highlighted that indiscriminate use in non-allergic conditions does occur in clinical practice. Accordingly, we have added this point to the Discussion section, hoping to provide a reference for ophthalmologists in clinical practice. (Line 371-378, manuscript) Reviewer #2: The manuscript provides a clear and concise overview of spontaneously reported AEs for 2 antihistamine drugs. Several comments and suggestions have been identified which should be considered by the authors. Response: We sincerely thank the reviewer for the thorough and insightful review of our manuscript. These detailed comments have substantially enhanced the rigor, transparency, and readability of this paper. We have fully addressed the major concerns by clarifying the screening criteria for ICSRs, defining the reference group used for the disproportionality analysis, and reorganizing the Discussion section to highlight the main findings and compare the two drugs. In addition, we have implemented all other suggestions regarding terminology, figure and table presentation, and methodological transparency. These revisions have markedly improved the quality of the manuscript. - The pathogenesis of AR is clearly described. To improve readability, consider to include a figure for the pathogenesis. Response: We greatly appreciate your positive evaluation and careful reading of our manuscript. In response to your suggestion, we have added a figure illustrating the pathogenesis of allergic rhinitis in the Introduction, to provide a visual overview of the key pathophysiological processes and enhance the readability of the article. The newly added schematic diagram of the pathogenesis is shown as follows: Fig 1: - Lines 67-73: The information in this section is not consistent as both drugs are second generation antihistamines and are selective H1-antagonists. In the current version it is specifically stated that azelastine is a second generation antihistamine and levocabastine is a selective H1-receptor antagonist. As this applies to both antihistamines the authors are advised to amend the manuscript accordingly. Response: We sincerely thank you for pointing out this inconsistency. We have revised the relevant sections accordingly, and in the revised version, both drugs are clearly identified as second-generation antihistamines and selective H1 receptor antagonists, thereby ensuring consistency throughout the text (Line 68-75, manuscript). The revised text reads as follows: Azelastine, a phthalazinone derivative, is a second‑generation antihistamine and a selective H1‑receptor antagonist. It exhibits unique pharmacological properties by inhibiting the synthesis and/or expression of various chemical mediators of allergic reactions [15], such as leukotrienes, kallikreins, cytokines, chemokines, and superoxide radicals [16, 17]. Levocabastine is also a second‑generation antihistamine and a selective, long‑acting H1‑receptor antagonist administered via the nasal and ocular routes. In controlled trials, levocabastine has been shown to be both efficacious and well‑tolerated in the treatment of allergic rhinitis and allergic conjunctivitis [18, 19]. - Lines 88-100: This information is better placed in the methods section of the manuscript. Please amend. Response: We greatly appreciate the reviewer’s suggestion. We have moved this content to the Data Sources subsection of the Methods section, thereby improving the logical flow and structural integrity of the manuscript. (Line 136-146, manuscript) - Lines 120-124: From the information in the methods section it can not be deduced when ICSRs are selected and excluded. Within spontaneous reports medicines can be either classified by the reporter as suspected or concomitant. Which reports are included in the current study? And are any exclusion criteria applied? Response: We thank the reviewer for this important comment. We have revised the Methods section to clarify the ICSR selection and exclusion criteria. Specifically, only reports in which azelastine or levocabastine was classified as a "suspected" drug were included in the analysis; reports where these drugs were listed solely as "concomitant" medications were excluded. To ensure data quality, we excluded duplicate reports and reports with incomplete adverse event information. These criteria have now been explicitly stated in the Methods section. (Line 161-167, manuscript) - Line 128: anti-VEGF drug need to be replaced by antihistamine drugs. Response: We greatly appreciate your careful reading of our manuscript, which has been immensely helpful in improving the scientific quality and accuracy of our article. We have corrected “anti-VEGF agents” to “antihistamines” (Line 129, manuscript). The revised text reads as follows: Therefore, a search was conducted of the records for each antihistamine, and individual AEs were identified employing the MedDRA SOC and PT criteria to examine the range of toxicities. - Disproportionality analysis: Please add which statistical software was used to calculate the ROR and PRR. Response: We thank the reviewer for this request. In the revised manuscript, we have added a detailed description of the data retrieval and statistical analysis pipeline in the Methods section. Briefly, we accessed the VigiAccess database (https://vigiaccess.org/) using Python 3.10 with the requests library to query all drug BASENAMEs in the WHODRUG dictionary. The JSON data returned from the front-end pages were parsed, converted into structured tables using the Pandas library, and exported to Excel for download. All disproportionality analyses, including the calculation of ROR, PRR, and their 95% confidence intervals, were subsequently performed using SAS 9.4 software. We hope this clarification meets the reviewer’s expectation. (Line 155-160, manuscript) - Line 137: Shouldn’t 5 drugs be replaced by 2 drugs? Response: We sincerely thank you for your careful reading of our manuscript, and we apologize for having made such an obvious error. We have now corrected “five drugs” to “two drugs” in the manuscript (Line 149, manuscript). The revised text reads as follows: This study utilized a retrospective quantitative research design. Descriptive analysis using Excel was conducted to analyze the characteristics of ADR profiles for two drugs. - Lines 170-173: The authors are advised to include the number of Adverse Events in addition to the number of reports currently included. Response: We sincerely thank you for your valuable suggestion and have added the number of adverse events to the manuscript (Line 212-214, manuscript). The revised text reads as follows: The numbers of adverse events covered in these ADR reports were 15,330 for azelastine and 1,292 for levocabastine. - Lines 175 and 176: Please remove the word significant from these sentences as no statistics are applied. Response: We sincerely thank you for your valuable suggestion. We have removed the word “significantly” from the sentence (Line 207-210, manuscript). The revised sentence reads as follows: Table 2 displays, among the 11, 592 reports of these two antihistamines, excluding 972 cases of unknown gender, the number of ADRs reported in females (7, 262, 62.65%) was higher than that of males (3, 376, 29.12%), with a male-to-female ratio of 2.15:1 and a gender difference. - Table 2: Consider shortening this table by combining age groups and years of reporting. Response: We sincerely thank you for your valuable suggestion. Since our age groups were classified according to the neonatal period, infancy, childhood, adolescence, adulthood, middle age, and old age, and each age stage is representative to some extent, we have not removed any age groups. However, we fully respect your opinion and recognize that the table was somewhat lengthy; therefore, we have merged the year groups, presenting only the data of the last ten years and combining the data before 2014 into a single group. The revised table is shown below. Should you have any further valuable suggestions, we will certainly give them careful consideration and make revisions to the best of our ability. (Line 226, manuscript, now Table 3) - Lines 202-210: MAJOR: The authors should specify which AEs were included in the analysis on neurological disorder and from the methods section and the results section it does not become clear which reference group is used for the analysis to calculate the ROR and PRR. Please specify. Response: We sincerely thank the reviewer for this important comment, which has substantially improved the methodological transparency of our manuscript. In the revised version, we have made the following specific additions to the Methods section: 1. Table 2: We have added a new table summarizing the principles of disproportionality measurement, including the calculation formulas for ROR and PRR, their standard errors, 95% confidence intervals, and the criteria for signal detection. 2. Neurological ADR definition: We have explicitly stated that all PTs belonging to the MedDRA SOC "Nervous system disorders" were included in the neurological disorder analysis. The specific PTs identified in our dataset (including burning sensation, hypoaesthesia, ageusia, migraine, paraesthesia, balance disorder, headache, parosmia, tremor, sedation, dysgeusia, dizziness, anosmia, and somnolence) have been integrated into the Disproportionality analysis subsection of the Methods. 3. Reference group clarification: We have clearly specified that the reference group for all disproportionality analyses consists of all other drug–ADR combinations in the WHO-VigiAccess database. The 2×2 contingency table is constructed with the study drug and target ADR as the index pair (cells *a* and *b*), while all other drugs and all other ADRs in the database serve as the background comparator (cells *c* and *d*). (Line 189-191, Line 195-207, manuscript) - Table 5: Consider to shorten this table by only presenting the 10 most frequently reported AEs. Response: We thank the reviewer for the suggestion. In accordance with the suggestion, we have streamlined Table 5 to present only the 10 most frequently reported adverse events. This revision makes the table more concise and enables readers to rapidly identify the safety signals of greatest clinical relevance. The complete list of adverse events remains available upon request. (Line 260, manuscript, now Table 6) - Figure 1 does not add relevant information, consider to delete. Response: We thank the reviewer for this suggestion. Upon re-evaluation, we agree that Figure 1 did not provide necessary additional information beyond what was already covered in the main text, and we have therefore removed it from the revised manuscript. - Table 6 & 7: These tables are quite extensive and have limited added value. Consider to move these tables to the supplementary information. Response: We thank the reviewer for the suggestion. We agree that Tables 6 and 7 were lengthy and could distract readers from the main findings. Therefore, we have moved these two tables to the supplementary materials (Supplementary S1 and S2 Tables). - Discussion section: MAJOR: start with a summary of the main findings and discuss the findings in relation to previous studies in the following paragraphs. Please amend. In addition, the information in lines 259-278 is a repetition of the information already described in the introduction section. Please delete. Response: We sincerely thank the reviewer for the important guidance on improving the Discussion section. We have comprehensively restructured this section accordingly. The revised Discussion opens with a brief summary of the main findings, followed by a paragraph-by-paragraph discussion in which each key result is compared with previous studies. In addition, we have completely removed the repetitive content originally in lines 259–278 and incorporated new research content related to both drugs. The specific revisions are too extensive to be detailed here. (Line 292-307, manuscript) - From the results section it is interesting to note the difference in AE reports between the two antihistamines. Consider to discuss this difference in the discussion section. Response: We sincerely thank the reviewer for this insightful suggestion. We agree that the differences in adverse event reporting between the two antihistamines warrant further exploration. We have comprehensively restructured the Discussion section and added a mechanistic discussion of the adverse reactions of both drugs based on literature from recent years. Further details can be found in the Discussion section. (Line 308-370, manuscript) - Lines 304-319: Please shorten this section and try to avoid repetition of the information already included in the results section. Response: We thank the reviewer for this suggestion. In accordance with your comment, we have deleted the paragraph in lines 304–319 of the original manuscript and replaced it with a combined analysis of the main results and previous studies. (Line 308-370, manuscript) - Lines 364-365: Consider to replace this specific information to the results section. Response: We thank the reviewer for this suggestion. We agree that the content originally in lines 364–365 is more appropriately placed in the Results section, as this information directly pertains to the study findings rather than to the discussion. We have moved this content to the relevant subsection in the Results section to ensure a smoother narrative and better alignment with the standard manuscript structure. The corresponding sentence in the Discussion section has been revised to avoid repetition. (Line 400-402, manuscript) - Line 365: It is not clear why the term biologics is introduced as both drugs studied are not biologics. Response: We sincerely thank the reviewer for pointing out this inaccuracy. We acknowledge that azelastine and levocabastine are small-molecule antihistamines, not biologics. The use of the term “biologics” in the original manuscript was a terminological error and has been corrected (Line402-404, manuscript). The revised sentence reads as follows: Conducting safety studies of pharmaceutical products, including cohort event monitoring, is essential for governments to determine the causal association between adverse responses and pharmaceuticals. Submitted filename: Response to Reviewers.docx 27 Jul 2026 Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess PONE-D-25-45000R1 Dear Dr. LI, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Rajeev Singh Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-45000R1 PLOS One Dear Dr. Li, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Rajeev Singh Academic Editor PLOS One